Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Maria Velinova

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

M. Velinova1, A. Bellon2, R. Nakov3, S. Schussler4, S. Schier-Mumzhiu3, C. Schelcher3, S.D. Koch3, A. Skerjanec5, J. Wang6, A. Krendyukov7, G.P. Otto3

Author affiliations

  • 1 Na, PRA Health Science, 000 - Groningen/NL
  • 2 Clinical Development, Hexal AG, 83607 - Holzkirchen/DE
  • 3 Clinical Development, Hexal AG, Holzkirchen/DE
  • 4 Clinical Development, Sandoz Inc., Princeton/US
  • 5 Clinical Development, Novartis AG, Basel/CH
  • 6 Biostatistics, Sandoz Inc., Princeton/US
  • 7 Medical Affairs, Hexal AG, Holzkirchen/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1496

Background

The pharmacokinetic (PK)/pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim (Ziextenzo®) and EU reference pegfilgrastim were shown to be similar in a pivotal phase I study. Similarity of efficacy and safety to the reference was demonstrated in two phase III studies in breast cancer patients receiving myelosuppressive chemotherapy. This 3-way study aimed to confirm similarity of PK/PD, safety and immunogenicity to US reference pegfilgrastim, and to bridge between the EU and US reference medicines.

Methods

This randomized, double-blind, 3-treatment, 6-sequence crossover phase I study included healthy volunteers (HVs) administered pegfilgrastim (biosimilar, EU reference, or US reference) once per treatment period. Primary objectives were to demonstrate PK similarity in AUC0-inf, AUC0-last and Cmax, and PD similarity in ANC AUEC0-last and ANC Emax. The study was powered (90%) to achieve confidence intervals within biosimilarity margins 0.8–1.25 in pairwise comparisons (biosimilar vs US reference, biosimilar vs EU reference, and US reference vs EU reference). Secondary objectives were safety, immunogenicity and additional PK/PD parameters.

Results

The study included 577 male and female HVs. PK and PD similarity were demonstrated for primary PK and PD parameters between Sandoz biosimilar, US reference, and EU reference (Table). The safety profile of Sandoz biosimilar pegfilgrastim was similar across groups. Incidence of antidrug antibodies was similar across groups (biosimilar: 31/512 [6.1%]; US reference: 36/511 [7.0%]; EU reference: 39/501 [7.8%]). Secondary PK/PD parameters were also similar.Table:

1815P Summary of PK and PD similarity

RatioCI 90%
Biosimilar / US-referenceAUC0-last1.06351.0087, 1.1213
AUEC0-last0.99970.9912, 1.0082
Biosimilar / EU-referenceAUC0-last1.04690.9929, 1.1038
AUEC0-last1.00120.9927, 1.0098
US-reference / EU-referenceAUC0-last0.98440.9336, 1.0380
AUEC0-last1.00150.9930, 1.0101

Conclusions

Sandoz biosimilar demonstrated similar PK/PD, safety, tolerability and immunogenicity to US reference and EU reference pegfilgrastim in this large 3-way crossover phase I study.

Clinical trial identification

EudraCT: 2016-003549-27.

Editorial acknowledgement

Caroline McGown of Spirit Medical Communications Ltd, supported by Hexal AG.

Legal entity responsible for the study

Hexal AG.

Funding

Hexal AG.

Disclosure

M. Velinova: Full / Part-time employment: PRA; Honoraria (self), compensation as lead Principal Investigator in the study: Sandoz Biopharmaceuticals. A. Bellon: Full / Part-time employment: Hexal AG. R. Nakov: Full / Part-time employment: Hexal AG. S. Schussler: Full / Part-time employment: Sandoz Inc. S. Schier-Mumzhiu: Full / Part-time employment: Hexal AG. C. Schelcher: Full / Part-time employment: Hexal AG. S.D. Koch: Full / Part-time employment: Hexal AG. A. Skerjanec: Full / Part-time employment: Novartis. J. Wang: Full / Part-time employment: Sandoz Inc. A. Krendyukov: Full / Part-time employment: Hexal AG. G.P. Otto: Full / Part-time employment: Hexal AG.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.